The HERA trial is a phase III, randomized, three-arm trial that studied the efficacy of 1 year versus 2 years of adjuvant trastuzumab versus control (no additional treatment) in women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer after completion of locoregional therapy and chemotherapy [3]. The gene discussed is ERBB2; the disease is breast carcinoma.